The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Open accessAbstract
The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy. In the last few years, immune‐checkpoint inhibitors (ICIs) have revolutionized cancer therapy and have gained an increased interest in the treatment of HCC. In 2020, the combination of atezolizumab (anti‐programmed death‐ligand 1) and bevacizumab (anti–vascular endothelial growth factor) improved overall survival over sorafenib, resulting in Food and Drug Administration (FDA) approval as a first‐line treatment for patients with advanced HCC. Despite these major advances, a better molecular and cellular characterization of the tumor microenvironment is still needed because it has a crucial role in the development and progression of HCC. Inflamed (hot) and noninflamed (cold) HCC tumors and genomic signatures have been associated with response to ICIs. However, there are no additional biomarkers to guide clinical decision‐making. Other immune‐targeting strategies, such as adoptive T‐cell transfer, vaccination, and virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, different cellular players, current available immunotherapies, and potential immunotherapy modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Monocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., & Tschopp, J. (2005) · Nature · doi:10.1038/nature04193 · Cited by 2,401
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, A. B., Mariotto, A., Lake, A. J., Wilson, R., Sherman, R. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx030 · Cited by 1,556
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Self-citationTranscriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Liver immunology and its role in inflammation and homeostasis
Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976 · cited 4×
“[198] Interestingly, in concordance with this work, Dudek et al. showed an increase of unconventional resident activated and exhausted hepatic CXCR6+ PD‐ 1+CD8+ T cells in the choline‐deficient high‐fat diet mouse model and human NASH tissue: these cells participate in tissue autoaggression and may favor HCC developme…”
BackgroundInfluentialRuiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Self-citationKuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., Zhang, Z., Xie, J., Wang, C., Chen, D., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.041 · Cited by 895
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Li, X.-D., Sun, L., Seth, R. B., Pineda, G., & Chen, Z. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508531102 · Cited by 840
Antigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“For example, it has been shown that depending on the context, senescent HSCs can either restrict or promote tumorigenesis through context‐dependent interactions with the immune system.[244,245] In the future, precision medicine will revolutionize HCC therapies, as accumulating evidence suggests that patients who recei…”
BackgroundSelf-citationLi, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Nault, J. C., Mallet, M., Pilati, C., Calderaro, J., Bioulac-Sage, P., Laurent, C., Laurent, A., Cherqui, D., Balabaud, C., & Zucman-Rossi, J. (2013) · Nature Communications · doi:10.1038/ncomms3218 · Cited by 695
Sharma, A., Seow, J. J. W., Dutertre, C.-A., Pai, R., Blériot, C., Mishra, A., Wong, R. M. M., Singh, G. S. N., Sudhagar, S., Khalilnezhad, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.040 · Cited by 677
Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., Simeone, D. M., Zou, W., & Welling, T. H. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.039 · Cited by 675
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652
Self-citationCsak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · cited 21×
“The level of oncostatin M was found to positively correlate with metastasis in patients with HCC.[75] Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous subset of myeloid cells that have been shown to inhibit T‐cell responses in cancer and HCC.”
BackgroundInfluentialInflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Zhu, X.-D., Zhang, J.-B., Zhuang, P.-Y., Zhu, H.-G., Zhang, W., Xiong, Y.-Q., Wu, W.-Z., Wang, L., Tang, Z.-Y., & Sun, H.-C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6521 · Cited by 556
Migratory fate and differentiation of blood monocyte subsets
Tacke, F., & Randolph, G. J. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.05.025 · Cited by 528
Dutertre, C.-A., Becht, E., Irac, S. E., Khalilnezhad, A., Narang, V., Khalilnezhad, S., Ng, P. Y., van den Hoogen, L. L., Leong, J. Y., Lee, B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.008 · Cited by 520
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 518 · cited 2×
“showed an increase of unconventional resident activated and exhausted hepatic CXCR6+ PD‐ 1+CD8+ T cells in the choline‐deficient high‐fat diet mouse model and human NASH tissue: these cells participate in tissue autoaggression and may favor HCC development by reinforcing CLD.[198,199] The majority of HCCs are not enri…”
BackgroundAdjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Kuang, D.-M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., Yin, X.-Y., & Zheng, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.041 · Cited by 499
van der Windt, D. J., Sud, V., Zhang, H., Varley, P. R., Goswami, J., Yazdani, H. O., Tohme, S., Loughran, P., O'Doherty, R. M., Minervini, M. I., et al. (2018) · Hepatology · doi:10.1002/hep.29914 · Cited by 477
Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012100 · Cited by 475
The Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Behary, J., Amorim, N., Jiang, X.-T., Raposo, A., Gong, L., McGovern, E., Ibrahim, R., Chu, F., Stephens, C., Jebeili, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20422-7 · Cited by 470
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Shi, F., Shi, M., Zeng, Z., Qi, R., Liu, Z., Zhang, J., Yang, Y., Tien, P., & Wang, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.25397 · Cited by 464
Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., Lim, K. H., Weber, A., Chow, P., Chung, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310814 · Cited by 461
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Kurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., Kitago, M., Shinoda, M., Kitagawa, Y., & Sakamoto, M. (2018) · Hepatology · doi:10.1002/hep.29904 · Cited by 454
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y., Liu, W., Zhang, Q., & Yang, Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0458-4 · Cited by 399
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398 · cited 1×
“Although platelets are now recognized as important regulators of HCC and HCC TME,[27] given the unique nature of platelets (they are pieces of megakaryocytes that lack a nucleus), they are reviewed elsewhere.”
BackgroundWang, H., Zhang, H., Wang, Y., Brown, Z. J., Xia, Y., Huang, Z., Shen, C., Hu, Z., Beane, J., Ansa-Addo, E. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.032 · Cited by 398
Liver inflammation abrogates immunological tolerance induced by Kupffer cells
Heymann, F., Peusquens, J., Ludwig‐Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., Martin, C., van Rooijen, N., Ochando, J. C., Randolph, G. J., et al. (2015) · Hepatology · doi:10.1002/hep.27793 · Cited by 398
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
Ye, B., Liu, X., Li, X., Kong, H., Tian, L., & Chen, Y. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.42 · Cited by 391
Shi, D., Shi, Y., Kaseb, A. O., Qi, X., Zhang, Y., Chi, J., Lu, Q., Gao, H., Jiang, H., Wang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3259 · Cited by 378
Zhang, W., Zhu, X.-D., Sun, H.-C., Xiong, Y.-Q., Zhuang, P.-Y., Xu, H.-X., Kong, L.-Q., Wang, L., Wu, W.-Z., & Tang, Z.-Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2904 · Cited by 374
Yang, L.-Y., Luo, Q., Lu, L., Zhu, W.-W., Sun, H.-T., Wei, R., Lin, Z.-F., Wang, X.-Y., Wang, C.-Q., Lu, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0836-0 · Cited by 370
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
Nault, J. C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E. S., Bioulac‐Sage, P., Roncalli, M., & Zucman‐Rossi, J. (2014) · Hepatology · doi:10.1002/hep.27372 · Cited by 354
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Schwaederle, M., Zhao, M., Lee, J. J., Lazar, V., Leyland-Jones, B., Schilsky, R. L., Mendelsohn, J., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 348
Song, M., He, J., Pan, Q., Yang, J., Zhao, J., Zhang, Y., Huang, Y., Tang, Y., Wang, Q., He, J., et al. (2021) · Hepatology · doi:10.1002/hep.31792 · Cited by 336
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.011 · Cited by 323
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V. V., Merle, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.267 · Cited by 319
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313
Population-based risk factors and resource utilization for HCC: US perspective
Sanyal, A., Poklepovic, A., Moyneur, E., & Barghout, V. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.506375 · Cited by 312
Sun, H., Huang, Q., Huang, M., Wen, H., Lin, R., Zheng, M., Qu, K., Li, K., Wei, H., Xiao, W., et al. (2019) · Hepatology · doi:10.1002/hep.30347 · Cited by 300
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Cai, L., Zhang, Z., Zhou, L., Wang, H., Fu, J., Zhang, S., Shi, M., Zhang, H., Yang, Y., Wu, H., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.012 · Cited by 288
Sun, C., Xu, J., Huang, Q., Huang, M., Wen, H., Zhang, C., Wang, J., Song, J., Zheng, M., Sun, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1264562 · Cited by 288
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H. (2009) · Hepatology · doi:10.1002/hep.22626 · Cited by 286
Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells
Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V., Jover-Cobos, M., Schurich, A., Singh, K. P., Thomas, N., Das, A., Chen, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3856 · Cited by 279
Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Arihara, F., Kagaya, T., Yamashita, T., Fushimi, K., & Kaneko, S. (2013) · Hepatology · doi:10.1002/hep.26153 · Cited by 273
Wu, Y., Kuang, D.-M., Pan, W.-D., Wan, Y.-L., Lao, X.-M., Wang, D., Li, X.-F., & Zheng, L. (2013) · Hepatology · doi:10.1002/hep.26192 · Cited by 266
He, G., Zhang, H., Zhou, J., Wang, B., Chen, Y., Kong, Y., Xie, X., Wang, X., Fei, R., Wei, L., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0256-0 · Cited by 263
Chew, V., Tow, C., Teo, M., Wong, H. L., Chan, J., Gehring, A., Loh, M., Bolze, A., Quek, R., Lee, V. K. M., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.013 · Cited by 259
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072076 · Cited by 256
Kim, H.-D., Song, G.-W., Park, S., Jung, M. K., Kim, M. H., Kang, H. J., Yoo, C., Yi, K., Kim, K. H., Eo, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.030 · Cited by 254
Hou, P.-P., Luo, L.-J., Chen, H.-Z., Chen, Q.-T., Bian, X.-L., Wu, S.-F., Zhou, J.-X., Zhao, W.-X., Liu, J.-M., Wang, X.-M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.004 · Cited by 253
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Shi, J.-Y., Gao, Q., Wang, Z.-C., Zhou, J., Wang, X.-Y., Min, Z.-H., Shi, Y.-H., Shi, G.-M., Ding, Z.-B., Ke, A.-W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3497 · Cited by 240
Liver-Mediated Adaptive Immune Tolerance
Zheng, M., & Tian, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02525 · Cited by 239
Bao, D., Zhao, J., Zhou, X., Yang, Q., Chen, Y., Zhu, J., Yuan, P., Yang, J., Qin, T., Wan, S., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0772-z · Cited by 235
Ding, T., Xu, J., Wang, F., Shi, M., Zhang, Y., Li, S.-P., & Zheng, L. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.08.011 · Cited by 232
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
Xiao, W.-K., Chen, D., Li, S.-Q., Fu, S.-J., Peng, B.-G., & Liang, L.-J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-117 · Cited by 231
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4012 · Cited by 229
Yamashita, T., Kudo, M., Ikeda, K., Izumi, N., Tateishi, R., Ikeda, M., Aikata, H., Kawaguchi, Y., Wada, Y., Numata, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-019-01642-1 · Cited by 229
Zhou, S., Yin, D., Hu, Z., Luo, C., Zhou, Z., Xin, H., Yang, X., Shi, Y., Wang, Z., Huang, X., et al. (2019) · Hepatology · doi:10.1002/hep.30630 · Cited by 226
Hage, C., Hoves, S., Strauss, L., Bissinger, S., Prinz, Y., Pöschinger, T., Kiessling, F., & Ries, C. H. (2019) · Hepatology · doi:10.1002/hep.30666 · Cited by 221
Qasim, W., Brunetto, M., Gehring, A. J., Xue, S.-A., Schurich, A., Khakpoor, A., Zhan, H., Ciccorossi, P., Gilmour, K., Cavallone, D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.001 · Cited by 208
Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Elliott, L. A., Doherty, G. A., Sheahan, K., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 208
Dong, P., Ma, L., Liu, L., Zhao, G., Zhang, S., Dong, L., Xue, R., & Chen, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030320 · Cited by 207
Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 206
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Lee, W.-C., Wang, H.-C., Hung, C.-F., Huang, P.-F., Lia, C.-R., & Chen, M.-F. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171291.72039.e2 · Cited by 185
Yu, M., Luo, H., Fan, M., Wu, X., Shi, B., Di, S., Liu, Y., Pan, Z., Jiang, H., & Li, Z. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.012 · Cited by 185
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
Schneider, C., Teufel, A., Yevsa, T., Staib, F., Hohmeyer, A., Walenda, G., Zimmermann, H. W., Vucur, M., Huss, S., Gassler, N., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301116 · Cited by 182
Beckebaum, S., Zhang, X., Chen, X., Yu, Z., Frilling, A., Dworacki, G., Grosse-Wilde, H., Broelsch, C. E., Gerken, G., & Cicinnati, V. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0872 · Cited by 181
Dai, H., Tong, C., Shi, D., Chen, M., Guo, Y., Chen, D., Han, X., Wang, H., Wang, Y., & Shen, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846926 · Cited by 179
Yin, C., Han, Q., Xu, D., Zheng, B., Zhao, X., & Zhang, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601479 · Cited by 178
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 176
Deng, H., Kan, A., Lyu, N., He, M., Huang, X., Qiao, S., Li, S., Lu, W., Xie, Q., Chen, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002305 · Cited by 176
A single cell atlas of the human liver tumor microenvironment
Massalha, H., Bahar Halpern, K., Abu‐Gazala, S., Jana, T., Massasa, E. E., Moor, A. E., Buchauer, L., Rozenberg, M., Pikarsky, E., Amit, I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209682 · Cited by 174
Zhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W., Yao, Y., Chen, Y., & Jiang, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000285 · Cited by 173
Ao, J.-Y., Zhu, X.-D., Chai, Z.-T., Cai, H., Zhang, Y.-Y., Zhang, K.-Z., Kong, L.-Q., Zhang, N., Ye, B.-G., Ma, D.-N., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0866 · Cited by 171
Chen, D.-P., Ning, W.-R., Jiang, Z.-Z., Peng, Z.-P., Zhu, L.-Y., Zhuang, S.-M., Kuang, D.-M., Zheng, L., & Wu, Y. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.007 · Cited by 170
Sprinzl, M. F., Reisinger, F., Puschnik, A., Ringelhan, M., Ackermann, K., Hartmann, D., Schiemann, M., Weinmann, A., Galle, P. R., Schuchmann, M., et al. (2013) · Hepatology · doi:10.1002/hep.26328 · Cited by 169
Ang, C., Klempner, S. J., Ali, S. M., Madison, R., Ross, J. S., Severson, E. A., Fabrizio, D., Goodman, A., Kurzrock, R., Suh, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26998 · Cited by 163
Butterfield, L. H., Ribas, A., Meng, W. S., Dissette, V. B., Amarnani, S. N., Vu, H. T., Seja, E., Todd, K., Glaspy, J. A., McBride, W. H., et al. (2003) · PubMed · Cited by 162
Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway
Shao, Y., Lo, C. M., Ling, C. C., Liu, X. B., Ng, K. T.-P., Chu, A. C. Y., Ma, Y. Y., Li, C. X., Fan, S. T., & Man, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.026 · Cited by 158
Chronically inflamed livers up-regulate expression of inhibitory B7 family members #
Kassel, R., Cruise, M. W., Iezzoni, J. C., Taylor, N., Pruett, T. L., & Hahn, Y. S. (2009) · Hepatology · doi:10.1002/hep.23173 · Cited by 155
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
Langhans, B., Nischalke, H. D., Krämer, B., Dold, L., Lutz, P. L., Mohr, R. U., Vogt, A., Toma, M. I., Eis‐Hübinger, A. M., Nattermann, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02427-4 · Cited by 151
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells
Sun, B., Yang, D., Dai, H., Liu, X., Jia, R., Cui, X., Li, W., Cai, C., Xu, J., & Zhao, X. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0026 · Cited by 150
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Leuchte, K., Staib, E., Thelen, M., Gödel, P., Lechner, A., Zentis, P., Garcia-Marquez, M. A., Waldschmidt, D., Datta, R. R., Wahba, R., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02734-1 · Cited by 150
Höchst, B., Schildberg, F. A., Sauerborn, P., Gäbel, Y. A., Gevensleben, H., Goltz, D., Heukamp, L. C., Türler, A., Ballmaier, M., Gieseke, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.033 · Cited by 147
Liu, L., Zhang, Z., Zheng, B., Shi, Y., Duan, M., Ma, L., Wang, Z., Dong, L., Dong, P., Shi, J.-Y., et al. (2018) · Hepatology · doi:10.1002/hep.30134 · Cited by 147
Davis, Z., Vallera, D. A., Miller, J. S., & Felices, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.011 · Cited by 143
Peng, Z.-P., Jiang, Z.-Z., Guo, H.-F., Zhou, M., Huang, Y., Ning, W.-R., Huang, J., Zheng, L., & Wu, Y. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.004 · Cited by 139
Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.004 · Cited by 137
Fu, X.-T., Song, K., Zhou, J., Shi, Y.-H., Liu, W.-R., Shi, G., Gao, Q., Wang, X.-Y., Ding, Z.-B., & Fan, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0771-8 · Cited by 137
Qin, S., Ren, Z., Feng, Y., Yau, T. C. C., Wang, B., Zhao, H., Bai, Y., Gu, S., Li, L., Hernandez, S., et al. (2021) · Liver Cancer · doi:10.1159/000513486 · Cited by 132
Balkwill, F. R., Montfort, A., & Capasso, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.10.007 · Cited by 130
Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma
Zhang, Z., Ma, L., Goswami, S., Ma, J., Zheng, B., Duan, M., Liu, L., Zhang, L., Shi, J., Dong, L.-Q., et al. (2019) · Oncoimmunology · doi:10.1080/2162402x.2019.1571388 · Cited by 121
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 119
Haider, C., Hnat, J., Wagner, R., Huber, H., Timelthaler, G., Grubinger, M., Coulouarn, C., Schreiner, W., Schlangen, K., Sieghart, W., et al. (2018) · Hepatology · doi:10.1002/hep.30166 · Cited by 117
FDA Approves Second CAR T-cell Therapy
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-155 · Cited by 115
Pedroza‐González, A., Zhou, G., Vargas-Méndez, E., Boor, P. P. C., Mancham, S., Verhoef, C. K., Polak, W. G., Grünhagen, D. J., Pan, Q., Janssen, H. L. A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008355 · Cited by 114
Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy
Arvanitakis, K., Mitroulis, I., & Germanidis, G. S. (2021) · Cancers · doi:10.3390/cancers13122899 · Cited by 114
Kampan, N. C., Xiang, S. D., McNally, O., Stephens, A. N., Quinn, M. A., & Plebanski, M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170712160621 · Cited by 109
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Zhang, C., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01295 · Cited by 109
Guan, X., Lu, Y., Zhu, H., Yu, S., Zhao, W., Chi, X., Xie, C., & Yin, Z. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s303588 · Cited by 109
Ouyang, F., Wu, R., Yuan, W., Liu, R., Yang, D., Xiao, C., Zheng, L., Li, B., Lao, X., & Kuang, D. (2016) · Nature Communications · doi:10.1038/ncomms13453 · Cited by 107
Identification of α‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy
Zhu, W., Peng, Y., Wang, L., Hong, Y., Jiang, X., Li, Q., Liu, H., Huang, L., Wu, J., Celis, E., et al. (2018) · Hepatology · doi:10.1002/hep.29844 · Cited by 107
The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma
Huang, Y., Ge, W., Zhou, J., Gao, B., Qian, X., & Wang, W. (2021) · Journal of Cancer · doi:10.7150/jca.51346 · Cited by 107
Märten, A., Ziske, C. G., Schöttker, B., Renoth, S., Weineck, S., Buttgereit, P., Schakowski, F., von Rücker, A., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00007 · Cited by 104
Platelets as Key Factors in Hepatocellular Carcinoma
Pavlovic, N., Rani, B., Gerwins, P., & Heindryckx, F. (2019) · Cancers · doi:10.3390/cancers11071022 · Cited by 104
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 103
Chen, C., Li, K., Jiang, H., Song, F., Gao, H., Pan, X., Shi, B., Bi, Y., Wang, H., Wang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1949-8 · Cited by 100
Kong, L., Zhu, X., Xu, H., Zhang, J., Lu, L., Wang, W., Zhang, Q., Wu, W., Wang, L., Fan, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059771 · Cited by 99
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Kamiya, T., Chang, Y.-H., & Campana, D. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0229 · Cited by 94
Faggioli, F., Palagano, E., Di Tommaso, L., Donadon, M., Marrella, V., Recordati, C., Mantero, S., Villa, A., Vezzoni, P., & Cassani, B. (2018) · Hepatology · doi:10.1002/hep.29636 · Cited by 90
Xu, G., Feng, D., Yao, Y., Li, P., Sun, H., Yang, H., Li, C., Jiang, R., Sun, B., & Chen, Y. (2019) · Oncogene · doi:10.1038/s41388-019-1072-3 · Cited by 87
Kunitani, H., Shimizu, Y., Murata, H., Higuchi, K., & Watanabe, A. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00062-4 · Cited by 85
Li, Q., Qian, C., Chen, Y., Bai, Y., Bao, Y., Lu, L., & Cao, X. (2012) · Blood · doi:10.1182/blood-2011-08-377242 · Cited by 84
Liver tumor infiltrating lymphocytes: Comparison of hepatocellular and cholangiolar carcinoma
Kasper, H., Drebber, U., Stippel, D. L., Dienes, H. P., & Gillessen, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5053 · Cited by 82
First-Ever CAR T-cell Therapy Approved in U.S.
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-126 · Cited by 79
Chemokines: A New Dendritic Cell Signal for T Cell Activation
Thaiss, C. A., Semmling, V., Franken, L., Wagner, H., & Kurts, C. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00031 · Cited by 78
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Zhou, D., Luan, J., Huang, C., & Li, J. (2020) · Gut and Liver · doi:10.5009/gnl20223 · Cited by 77
Xue, H., Lin, F., Tan, H., Zhu, Z.-Q., Zhang, Z.-Y., & Zhao, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154815 · Cited by 76
Thimme, R., Neagu, M., Boettler, T., Neumann‐Haefelin, C., Kersting, N., Geißler, M., Makowiec, F., Obermaier, R., Hopt, U. T., Blum, H. E., et al. (2008) · Hepatology · doi:10.1002/hep.22535 · Cited by 73
Mantovani, S., Oliviero, B., Lombardi, A., Varchetta, S., Mele, D., Sangiovanni, A., Rossi, G. E., Donadon, M., Torzilli, G., Soldani, C., et al. (2018) · Hepatology · doi:10.1002/hep.30235 · Cited by 73
Mantovani, S., Oliviero, B., Varchetta, S., Mele, D., & Mondelli, M. U. (2020) · Cancers · doi:10.3390/cancers12040926 · Cited by 71
Liu, Y., Daley, S., Evdokimova, V. N., Zdobinski, D. D., Potter, D. M., & Butterfield, L. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.712 · Cited by 67
Zhou, Z., Xin, H., Li, J., Hu, Z., Luo, C., & Zhou, S. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02355-3 · Cited by 66
Butterfield, L. H., Ribas, A., Potter, D. M., & Economou, J. S. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0337-9 · Cited by 65
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Lin, M., Liang, S., Wang, X., Liang, Y., Zhang, M., Chen, J., Niu, L., & Xu, K. (2017) · Oncotarget · doi:10.18632/oncotarget.17804 · Cited by 63
Dendritic cells as cancer therapeutics
Bryant, C. E., Sutherland, S., Kong, B., Papadimitrious, M. S., Fromm, P. D., & Hart, D. N. J. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2018.02.015 · Cited by 61
Nakamoto, Y., Mizukoshi, E., Kitahara, M., Arihara, F., Sakai, Y., Kakinoki, K., Fujita, Y., Marukawa, Y., Kazumori, A. R. A. I., Yamashita, T., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04246.x · Cited by 61
van Rhee, F., Casper, C., Voorhees, P. M., Fayad, L., Gibson, D., Kanhai, K. J. K., & Kurzrock, R. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30257-1 · Cited by 61
Cited by
Constructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
Metadata
- Authors
- Donne, R., & Lujambio, A.
- Venue
- Hepatology
- Published
- 2023-04-17
- Volume
- 77
- Issue
- 5
- Pages
- 1773-1796
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4292553490
- Cited by
- 631
- References
- 233
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.